CRESCENT BIOPHARMA, INC. (CBIO) Financial Statements
CRESCENT BIOPHARMA, INC. (CBIO) files with the U.S. Securities and Exchange Commission under CIK 0001253689. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- $10.84 million
- Net Income
- -$153.94 million
- Total Assets
- $240.29 million
- Net Cash from Operations
- -$71.53 million
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Jul 30, 2026. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for CBIO in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History